Year archive

RELIEF Therapeutics Holding AG — 2022 filings

All 112 regulatory filings released by RELIEF Therapeutics Holding AG (RLF) in 2022, sourced directly from the official regulator.

112 Filings

2022 Period

2022 filings (112)

Filing	Released	Lang
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-12-27	English
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVATM for Patients with Urea Cycle Disorders Regulatory Filings	2022-12-27	English
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-12-27	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements Legal Proceedings Report	2022-12-20	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements Legal Proceedings Report	2022-12-20	English
Relief Therapeutics to Participate in January Investor Meetings Regulatory Filings	2022-12-14	English
Relief Therapeutics to Participate in January Investor Meetings Report Publication Announcement	2022-12-14	English
Relief Therapeutics Announces Issuance of Shares from Authorized Capital Share Issue/Capital Change	2022-12-13	English
Relief Therapeutics Announces Issuance of Shares from Authorized Capital Share Issue/Capital Change	2022-12-13	English
Relief Therapeutics Announces Executive Leadership Team Changes Board/Management Information	2022-12-08	English
Relief Therapeutics Announces Executive Leadership Team Changes Board/Management Information	2022-12-08	English
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival Regulatory Filings	2022-11-21	English
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival Environmental & Social Information	2022-11-21	English
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-11-16	English
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-11-16	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Regulatory Filings	2022-11-14	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Regulatory Filings	2022-11-14	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement Regulatory Filings	2022-11-08	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement Legal Proceedings Report	2022-11-08	English
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Regulatory Filings	2022-11-07	English
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Regulatory Filings	2022-11-07	English
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement Regulatory Filings	2022-10-26	English
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement Legal Proceedings Report	2022-10-26	English
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission Share Issue/Capital Change	2022-10-25	English
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission Regulatory Filings	2022-10-25	English
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer Board/Management Information	2022-10-14	English
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer Board/Management Information	2022-10-14	English
Relief Announces U.S. Launch of PKU GOLIKE Regulatory Filings	2022-10-10	English
Relief Announces U.S. Launch of PKU GOLIKE Share Issue/Capital Change	2022-10-10	English
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. Regulatory Filings	2022-10-06	English
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. M&A Activity	2022-10-06	English
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate Regulatory Filings	2022-10-03	English
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate Regulatory Filings	2022-10-03	English
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago Regulatory Filings	2022-09-22	English
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago Regulatory Filings	2022-09-22	English
Relief Reports Half-Year 2022 Results and Provides Corporate Update Earnings Release H1 2022	2022-09-15	English
Relief Reports Half-Year 2022 Results and Provides Corporate Update Earnings Release H1 2022	2022-09-15	English
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum Report Publication Announcement	2022-09-12	English
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Regulatory Filings	2022-09-07	English
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-08-24	English
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission Capital/Financing Update	2022-08-24	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation Legal Proceedings Report	2022-08-22	English
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation Legal Proceedings Report	2022-08-22	English
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access Board/Management Information	2022-08-17	English
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access Board/Management Information	2022-08-17	English
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease Regulatory Filings	2022-08-12	English
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease Regulatory Filings	2022-08-12	English
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100 (Aviptadil) Regulatory Filings	2022-08-03	English
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil) Regulatory Filings	2022-08-03	English
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease Regulatory Filings	2022-07-28	English
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs Regulatory Filings	2022-07-28	English
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease Regulatory Filings	2022-07-28	English
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F Regulatory Filings	2022-07-21	English
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F Regulatory Filings	2022-07-21	English
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs) Legal Proceedings Report	2022-07-18	English
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine Board/Management Information	2022-07-18	English
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs) Legal Proceedings Report	2022-07-18	English
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU M&A Activity	2022-07-13	English
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU Regulatory Filings	2022-07-13	English
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form Environmental & Social Information	2022-07-08	English
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form Legal Proceedings Report	2022-07-08	English
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-07-04	English
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk Legal Proceedings Report	2022-07-04	English
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-07-04	English
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001 Regulatory Filings	2022-06-21	English
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001 Legal Proceedings Report	2022-06-21	English
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-06-17	English
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-06-17	English
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil Regulatory Filings	2022-06-13	English
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil Legal Proceedings Report	2022-06-13	English
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001 Regulatory Filings	2022-06-08	English
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001 Regulatory Filings	2022-06-08	English
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA AGM Information	2022-06-01	English
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA AGM Information	2022-06-01	English
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients Regulatory Filings	2022-05-31	English
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients Legal Proceedings Report	2022-05-31	English
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19 Regulatory Filings	2022-05-26	English
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19 Legal Proceedings Report	2022-05-26	English
Relief Therapeutics Expands U.S. Commercial Team Board/Management Information	2022-05-23	English
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-05-11	English
Relief Therapeutics to Participate in Industry and Investor Conferences in May Regulatory Filings	2022-05-09	English
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference Regulatory Filings	2022-05-06	English
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA AGM Information	2022-05-06	English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) Regulatory Filings	2022-04-27	English
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing Board/Management Information	2022-04-26	English
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil Legal Proceedings Report	2022-04-22	English
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Regulatory Filings	2022-04-12	English
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process Legal Proceedings Report	2022-04-05	English
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' Regulatory Filings	2022-04-01	English
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 Legal Proceedings Report	2022-04-01	English
Relief Reports Full-Year 2021 Results and Provides Corporate Update Earnings Release FY 2021	2022-03-31	English
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU Legal Proceedings Report	2022-03-28	English
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office Regulatory Filings	2022-03-24	English
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales Board/Management Information	2022-03-21	English
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Regulatory Filings	2022-03-21	English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients Legal Proceedings Report	2022-03-17	English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU M&A Activity	2022-03-15	English
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment Regulatory Filings	2022-02-16	English
Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office Regulatory Filings	2022-02-08	English
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock Board/Management Information	2022-02-02	English
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease Regulatory Filings	2022-02-01	English
Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA AGM Information	2022-01-31	English
Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge Regulatory Filings	2022-01-27	English
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences Regulatory Filings	2022-01-27	English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs Environmental & Social Information	2022-01-24	English
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies Legal Proceedings Report	2022-01-19	English
Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit Regulatory Filings	2022-01-14	English
Relief Comments on Lawsuit Filed Against It by NeuroRx Legal Proceedings Report	2022-01-12	English
Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies Legal Proceedings Report	2022-01-06	English
Relief Therapeutics to Participate in Virtual Investor Conferences in January Report Publication Announcement	2022-01-05	English
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use Legal Proceedings Report	2022-01-04	English
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA AGM Information	2022-01-03	English